Save
Venous thromboembolism in patients with liver diseases
Author(s): ,
R. Barba
Affiliations:
Department of Internal Medicine, Hospital Universitario Rey Juan Carlos, Móstoles, Spain
Correspondence: Raquel Barba, Hospital Universitario Rey Juan Carlos, C/GLadiolo s/n Móstoles, Madrid 28933, Spain|Tel.: +34 91 481 6225|E‐mail: raquel.barba@hospitalreyjuancarlos.es
,
Asuncion Gonzalvez‐Gasch
Affiliations:
Department of Internal Medicine, Hospital General Villalba, Collado Villalba, Spain
,
D. Joya Seijo
Affiliations:
Department of Internal Medicine, Hospital Universitario Rey Juan Carlos, Móstoles, Spain
,
J. Marco
Affiliations:
Department of Internal Medicine, Hospital Clínico de San Carlos, San Carlos, Spain
,
J. Canora
Affiliations:
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
,
S. Plaza
Affiliations:
Department of Internal Medicine, Hospital Severo Ochoa, Leganés, Spain
,
M. Angelina García
Affiliations:
Department of Internal Medicine, Hospital Universitario Rey Juan Carlos, Móstoles, Spain
A. Zapatero
Affiliations:
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
ISTH Academy. Barba R. Oct 4, 2018; 234175
Raquel Barba
Raquel  Barba

Access to Premium content is currently a membership benefit.


Click here to join ISTH or renew your membership.

Journal Abstract
Discussion Forum (0)
Rate & Comment (0)


Background and Aims
Patients with liver disease were traditionally believed to be protected against development of blood clots, but some studies have shown a potential increased risk of venous thrombotic complications. We assessed the risk of venous thromboembolism (VTE) in patients with liver disease.
Methods
Data in discharge reports of patients with liver disease and control patients without liver disease were analyzed from the national inpatient sample. Incidence of VTE was compared in patients with mild, moderate‐severe or no liver disease, and the impact on in‐hospital mortality and length of stay was calculated.
Results
The overall incidence of VTE for patients with no liver disease, mild liver disease and moderate‐severe liver disease was 2.7, 2.4 and 0.9 per 100 patient discharges, respectively. In the presence of VTE, in‐hospital mortality was 10.8%, 5.8%, and 21.7% for the no liver disease, mild disease and moderate‐severe liver disease, respectively. The presence of VTE resulted in an increase in mortality for patients with no liver disease (OR, 1.16; 95% CI, 1.14–1.18) and moderate‐severe liver disease (OR, 1.63; CI 95%, 1.42–1.88).
Conclusions
Patients with moderate‐severe liver disease have a lower risk of VTE than those without liver disease. Development of thrombosis during admission increased the risk of in‐hospital mortality.
Keyword(s)
data base, liver cirrhosis, liver disease, mortality, venous thromboembolism
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings